10-Q: Dermata Therapeutics Pivots to OTC Amidst Going Concern

Dermata Therapeutics, Inc. announced a strategic shift to over-the-counter dermatology products following positive Phase 3 trial results for XYNGARI, while reporting continued net losses and a going concern warning.

Summary

• The company announced a strategic pivot in September 2025 to focus on developing and distributing over-the-counter (OTC) pharmaceutical dermatology products.
• Positive topline results were achieved in March 2025 for the XYNGARI Phase 3 STAR-1 clinical trial for moderate-to-severe acne, meeting all co-primary endpoints.
• Net loss for the nine months ended September 30, 2025, was $5.7 million, a decrease from $9.1 million for the same period in 2024.
• Cash and cash equivalents increased to $4.7 million as of September 30, 2025, from $3.2 million at December 31, 2024.
• The accumulated deficit reached $71.4 million as of September 30, 2025.
• Management expects current cash and cash equivalents to fund operations into the second quarter of 2026.
• Substantial doubt exists about the company's ability to continue as a going concern for the one-year period following the financial statements' issuance.
• The company plans to launch its first OTC product, a once-weekly topical acne kit, in mid-2026.
• A notice of material breach and demand for cure was received from Villani, Inc. regarding the License Agreement, which the company disputes.

Sentiment

Score: 4

Explanation: While financial losses decreased and cash increased, the company faces substantial doubt about its going concern status, a critical legal dispute over its core technology license, and significant risks associated with its strategic pivot to OTC, including intense competition and regulatory hurdles. The positive clinical trial results are overshadowed by the decision to withdraw the IND and the associated legal challenge.

Positives

• Positive topline results from the XYNGARI Phase 3 STAR-1 clinical trial for moderate-to-severe acne, demonstrating statistically significant results across all three co-primary endpoints at weeks 4, 8, and 12 compared with placebo.
• Net loss for the nine months ended September 30, 2025, decreased to $5.7 million from $9.1 million in the prior year, representing a $3.4 million improvement.
• Cash and cash equivalents increased to $4.7 million as of September 30, 2025, from $3.2 million at December 31, 2024.
• Net cash used in operating activities decreased to $6.4 million for the nine months ended September 30, 2025, from $8.2 million in the prior year.
• Research and development expenses decreased by $3.6 million for the nine months ended September 30, 2025, primarily due to the completion of the STAR-1 clinical trial.
• The strategic pivot to OTC products aims to accelerate commercialization, reduce regulatory burden, and decrease company expenses, while addressing broader consumer segments.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $71.4 million as of September 30, 2025.
• There is substantial doubt about the company's ability to continue as a going concern for the one-year period following the date of the financial statements' issuance.
• A notice of material breach and demand for cure was received from Villani, Inc. regarding the License Agreement, alleging failure to pursue a prescription product business and other breaches, which could lead to termination of rights to the core Spongilla technology.
• The company is dependent on raising additional capital to sustain operations beyond the second quarter of 2026.
• The collaboration agreement with Revance Therapeutics for a Phase 2a clinical trial evaluating XYNGARI with DAXXIFY has been placed on hold due to the strategic shift.
• Selling, general and administrative expenses increased by $0.2 million for the nine months ended September 30, 2025, primarily due to increased marketing expenses for the upcoming OTC product launch.

Risks

• The company has a lack of operating history and expects to incur significant operating losses for the foreseeable future, requiring substantial additional capital.
• There is uncertainty that any planned OTC formulation, dosage, combination, or indications will fall within the scope of an applicable OTC monograph, or will not require a new drug application, which could delay or prevent launch.
• Positive clinical data generated in the Rx setting may not be predictive of consumer experience or commercial performance in the OTC context, and such data may impose limits on permissible OTC claims.
• The company's ability to timely secure and scale manufacturing, packaging, and quality systems suitable for OTC commercialization is critical and poses a risk.
• Successfully executing the strategic pivot from Rx to OTC requires compliance with applicable federal, state, and international OTC requirements and standards, which is a significant challenge.
• The company's ability to establish and maintain distribution and sales channels, including direct-to-consumer e-commerce, professional/clinic channels, and retail partners, is uncertain.
• The ability to acquire sufficient quantities of Spongilla raw material could be negatively impacted by enhanced export controls and economic sanctions against Russia, as the exclusive supplier is a Russian entity.
• If the company is found to have breached its obligations under the License Agreement with Villani, Inc., it could lose rights to its Spongilla technology, which is central to its product candidates.
• The company faces intense competition from large consumer products companies in the U.S. and international OTC markets, many of which have greater financial resources.
• Counterfeit, intellectual-property-infringing, or other unauthorized versions of products, particularly in the OTC business, could harm consumers and adversely affect the company.
• Disruptions to distribution operations could adversely affect the company's ability to deliver products to consumers and customers.

Future Outlook

The company plans to launch its first OTC product, a once-weekly topical acne kit, in mid-2026. It expects to continue incurring net losses for the foreseeable future and will need additional financing to support operations beyond Q2 2026. The strategic pivot to OTC products is anticipated to accelerate commercialization, reduce regulatory burden, and decrease expenses, while leveraging Spongilla technology for broader dermatology applications. The collaboration with Revance Therapeutics for a Phase 2a clinical trial is currently on hold, but the company continues to evaluate the platform for needle-free botulinum toxin delivery.

Management Comments

• "We believe we can leverage the data generated with our Spongilla technology to create OTC pharmaceutical products that are effective and that patients want to use."
• "This repositioning should accelerate our path to commercialization, reduce our regulatory burden, and decrease company expenses, all while being able to address broader consumer segments in the dermatology space."
• "While this is a major shift in strategy for our company, we believe it is the best path forward to meet our mission of providing patients with efficacious and safe treatment options."
• "We plan to launch our first product in the middle of 2026 which will consist of a once-weekly, topical acne kit that can be used by patients with mild, moderate, or severe acne."
• "We still believe there is a potential to utilize our Spongilla technology for the topical delivery of botulinum toxin, but with our strategic decision to withdraw the XYNGARI IND, we are currently evaluating the regulatory and commercial opportunities for this program."

Industry Context

The dermatology market is experiencing a significant shift, with consumers increasingly opting for over-the-counter (OTC) treatments for common conditions like acne, psoriasis, and rosacea. This trend is driven by factors such as lower price points, a desire for self-administration, difficulties in securing dermatologist appointments, and enhanced convenience. The company's strategic pivot to OTC products aligns with this evolving consumer preference, aiming to bridge the gap between prescription therapies and accessible, scientifically-backed OTC solutions.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• On November 10, 2025, the company received a notice of material breach and demand for cure from Villani, Inc., alleging breaches of the License Agreement due to the company's strategic shift to focus on over-the-counter pharmaceutical products. Allegations include failure to use Commercially Reasonable Efforts to pursue a prescription product business, failure to provide advance notice of regulatory submissions, use of Licensed Know-How outside the defined Field, and that anticipated OTC kits do not qualify as Licensed Products.
• On November 11, 2025, Villani delivered an additional notice requesting the reversion and assignment of all assets regarding Spongilla-based products back to Villani, preservation of all Spongilla inventory, and preservation of all related documents, data, and tangible materials.
• The company disputes these allegations and is engaged in discussions with Villani to resolve the disputes. If no resolution is reached, either party may file for arbitration or termination of the License Agreement. The License Agreement remains in full force as of the filing date, and the final outcome is unpredictable.

Related Party Transactions

• The company entered into a Master Services Agreement with Wilder & Partners, LLC, an agency assisting with branding, marketing, and product design for the upcoming product launch. The founding partner of Wilder is the CEO's son-in-law. Approximately $0.5 million in marketing expenses related to Wilder were incurred for the three and nine months ended September 30, 2025, with about $0.2 million outstanding.
• Certain company insiders, including the CEO, CFO, and members of the board of directors, participated in the January 2025 PIPE financing. They purchased an aggregate of 122,047 shares of Common Stock and warrants for approximately $1.55 million, at the same purchase price as other investors.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and uncertainty regarding the company's going concern status. The legal dispute over the core Spongilla technology license could significantly impact the company's long-term viability and shareholder value.
• Future customers of OTC products may benefit from new, scientifically-backed dermatology treatments, but the success of the strategic pivot and product launch is uncertain.
• The company's reliance on a Russian entity for its exclusive supply of Spongilla raw material introduces geopolitical risk, potentially impacting product availability and supply chain stability.
• Creditors face increased risk due to the company's recurring losses and the substantial doubt about its ability to continue as a going concern.

Next Steps

• Launch the first OTC product, a once-weekly topical acne kit, in mid-2026.
• Finalize the components and container closure for the initial acne kit.
• Complete the development of the new brand identity with a branding agency.
• Initiate the manufacturing process for the initial OTC product launch.
• Continue discussions with Revance Therapeutics regarding future opportunities for the collaboration on topical botulinum toxin delivery.
• Explore additional uses for the Spongilla technology platform as a needle-free alternative for topical delivery of large molecules.
• Seek additional capital through equity or debt financings, and/or new collaborations to fund future operations.
• Resolve the dispute with Villani, Inc. regarding the alleged material breach of the License Agreement.

Key Dates

Recommendation

While the company has shown some positive financial trends (reduced net loss, increased cash) and achieved positive Phase 3 clinical results, the strategic pivot to OTC introduces significant new regulatory and commercial risks. The most pressing concern is the 'going concern' warning and the material breach notice from Villani, Inc., which directly threatens the company's ability to use its core Spongilla technology. The success of the OTC pivot is highly uncertain given intense competition and the need for substantial additional capital. Investors should hold, awaiting clarity on the legal dispute and concrete progress on the OTC commercialization strategy, while acknowledging the high-risk, high-reward nature of this transition.

Keywords

Dermata Therapeutics, DRMA, biotechnology, dermatology, OTC products, Spongilla technology, acne treatment, clinical trials, financial results, going concern, capital raise, SEC filing, Q3 2025, XYNGARI, Revance Therapeutics, Villani Inc., license agreement, reverse stock split